Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein.

Abstract

BACKGROUND/AIM:

The present study determined the efficacy of extracts of Astragalus membranaceus (AM) and Curcuma wenyujin (CW), a traditional Chinese medicine herbal mixture, at different tumor stages of an orthotopic nude mouse model of human ovarian cancer expressing red fluorescent protein.

MATERIALS AND METHODS:

The tumor-bearing mice were treated with cisplatinum (CDDP), AM, CW, or a combination of AM and CW in each of three tumor stages, using the same regimen. Group 1 received saline as negative control. Group 2 received CDDP i.p. as positive control with a dose of 2 mg/kg, every three days. Group 3 received AM daily via oral gavage, at a dose of 9120 mg/kg. Group 4 received CW daily via oral gavage, at a dose of 4560 mg/kg. Groups 5, 6 and 7 received combinations of AM and CW daily via oral gavage at low (AM, 2280 mg/kg; CW, 1140 mg/kg), medium (AM, 4560 mg/kg; CW 2280 mg/kg), and high (AM, 9120 mg/kg; CW, 4560 mg/kg) doses. The expression of angiogenesis- and apoptosis-related genes in the tumors were analyzed by immunohistochemistry for matrix metalloproteinase 2 (MMP-2), vascular endothelial growth factor (VEGF) fibroblast growth factor 2 (FGF-2), B-cell lymphoma 2 (Bcl-2) and cyclooxygenase 2 (Cox-2), and by polymerase chain reaction for MMP-2, FGF-2 and Bcl-2.

RESULTS:

CDDP, AM, and its combination with CW-induced significant growth inhibition of Stage I tumors. Strong efficacy of the combination of AM and CW at high dose was observed. Monotherapy with CDDP, AM, CW, and the combination treatments did not significantly inhibit Stage II and III tumors. The expression of MMP-2, VEGF, FGF-2, and Cox-2 was significantly reduced in Stage I tumors treated with AM, CW, and their combination, suggesting a possible role of these angiogenesis- and apoptosis-related genes in the observed efficacy of the agents tested.

CONCLUSION:

This study is the first report on the efficacy of anticancer agents at different stages of ovarian cancer in an orthotopic mouse model. As the tumor progressed, it became treatment-resistant, similar to the clinical situation, further demonstrating the utility of the model and the need for agents acrtive in advanced-stage ovarian cancer.

• Authors: Gang Yin, Decai Tang, Jianguo Dai, Min Liu, Mianhua Wu, Y U Sun, Zhijian Yang, Robert M Hoffman, Lin Li, Shuo Zhang, Xiuxia Guo
• Journal: Anticancer research (Anticancer Res) Vol. 35 Issue 6 Pg. 3193-207 (Jun 2015) ISSN: 1791-7530 [Electronic] Greece
• PMID: 26026079 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• Drugs, Chinese Herbal
• Luminescent Proteins
• Vascular Endothelial Growth Factor A
• red fluorescent protein
• Fibroblast Growth Factor 2
• Cyclooxygenase 2
• PTGS2 protein, human
• Matrix Metalloproteinase 2

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Apoptosis (drug effects)
• Astragalus propinquus (chemistry)
• Cell Line, Tumor
• Curcuma (chemistry)
• Cyclooxygenase 2 (biosynthesis)
• Disease Models, Animal
• Drugs, Chinese Herbal (administration & dosage, chemistry)
• Female
• Fibroblast Growth Factor 2 (biosynthesis)
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Luminescent Proteins (metabolism)
• Matrix Metalloproteinase 2 (biosynthesis)
• Mice
• Neoplasm Staging
• Neovascularization, Pathologic (drug therapy, genetics, pathology)
• Ovarian Neoplasms (drug therapy, genetics, pathology)
• Vascular Endothelial Growth Factor A (biosynthesis)